ReviewJournal of asthma and allergy2021
Current Perspectives on the Systemic Management of Atopic Dermatitis.
Review in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus.Dermatology (Basel, Switzerland) · 2024Guideline
- Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review.PloS one · 2024Pooled it
- Basophils in atopic dermatitis: Immunologic roles and clinical implications.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026Review
- An online program focusing on modifiable lifestyle and environmental interventions was associated with improved pediatric eczema symptoms: results from a retrospective observational study.Frontiers in allergy · 2026Article
- Skin-Immune-Neuro-Gastro-Endocrine (SINGE) System: Lighting the Fire on Atopic Dermatitis Research.Dermatology practical & conceptual · 2025Review
- Methotrexate in the treatment of atopic dermatitis.Postepy dermatologii i alergologii · 2025Review
- Contemporary and prospective use of azathioprine (AZA) in viral, rheumatic, and dermatological disorders: a review of pharmacogenomic and nanotechnology applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Optimized nanostructured lipid carriers from aceh traditional coconut (Pliek) oil: a promising topical formulations for atopic dermatitis.Archives of dermatological research · 2025Article
- OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.American journal of clinical dermatology · 2024Review
- Association between dietary inflammatory index and all-cause mortality in US adults with dermatitis: a population-based cohort study.Frontiers in nutrition · 2024Article
- From neglect to spotlight: the underappreciated role of B cells in cutaneous inflammatory diseases.Frontiers in immunology · 2024Review
- Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis.Expert review of clinical pharmacology · 2023Review
- Off-label medications in the treatment of hospitalized children with atopic dermatitis.Postepy dermatologii i alergologii · 2023Article
- Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Article
- IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient.Clinical immunology (Orlando, Fla.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common disease of childhood, and some patients experience a prolonged clinical course into adolescence and adulthood. Systemic management is required when AD is not adequately controlled with topical medications. Our aim is to provide a comprehensive review of commonly used systemic immunomodulating agents in childhood and adult AD, including cyclosporine A (CsA), azathioprine (AZA), methotrexate (MTX) and mycophenolate mofetil (MMF), which are prescribed off-label in the United States, as well as dupilumab, an FDA-approved biologic. We will also provide a brief overview of emerging systemic therapies currently under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.